isobutyl-octyl ether | 90689-24-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: isobutyl-octyl ether
• 英文别名: Isobutyl-octyl-aether；1-Isobutoxy-octane；1-(2-methylpropoxy)octane
• CAS: 90689-24-0
• 化学式: C₁₂H₂₆O
• 分子量: 186.338
• InChiKey: FOQPXCQHTBSLMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  13
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-溴辛烷 、 sodium isobutoxide 生成 isobutyl-octyl ether
  参考文献：
  名称：

  Preparation and Properties of Some Octyl Ethers¹

  摘要：

  DOI：

  10.1021/ja01115a508

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20120039848A1

  公开（公告）日：2012-02-16

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了公式（I）的化合物或其药学上可接受的盐、酯或前药，它们能够抑制RNA含量病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰了丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给受试者投予包含本发明化合物的制药组合物来治疗HCV感染的方法。
• Biodegradable lipids for delivery of nucleic acids
  申请人：TRANSLATE BIO, INC.

  公开号：US10022455B2

  公开（公告）日：2018-07-17

  The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by administering to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.

  本发明提供了一种生物可降解的化合物，其化学式为I，以及其子式：化学式（I）或其药学上可接受的盐，其中每个X独立地为O或S，每个Y独立地为O或S，每个R1独立地在此处定义；以及包含化学式I或其子式的阳离子脂质的脂质体组合物，以及通过向主体给予包含化学式I或其子式的阳离子脂质的脂质体来递送药剂（例如核酸，包括mRNA）的方法，在此过程中，药剂被封装在脂质体内。
• COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM
  申请人：Takayama Masami

  公开号：US20090318513A1

  公开（公告）日：2009-12-24

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  一种由通式（I）表示的化合物：其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。该化合物为一种前药、药物可接受的盐或其溶剂。
• Compounds exhibiting thrombopoietin receptor agonism
  申请人：Takayama Masami

  公开号：US20070043087A1

  公开（公告）日：2007-02-22

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  化合物的一般式(I)表示的复合物，其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。这是一个前药、药物可接受的盐或其溶剂。
• AMINOALCOHOL LIPIDOIDS AND USES THEREOF
  申请人：Mahon Kerry Peter

  公开号：US20110293703A1

  公开（公告）日：2011-12-01

  Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

  本文描述了通过将胺与环氧末端化合物反应制备氨基醇脂质体的方法。还提供了从商业起始材料制备氨基醇脂质体的方法。氨基醇脂质体可以从外消旋或立体化学纯的环氧化合物制备。氨基醇脂质体或其盐形式最好是可生物降解和生物相容的，并可用于各种药物输送系统。鉴于这些氨基醇脂质体化合物的氨基基团，它们特别适用于多核苷酸的输送。已经制备了包含创新脂质体和多核苷酸的复合物、胶束、脂质体或粒子。创新脂质体也可以用于制备药物输送的微粒。鉴于它们能够缓冲其周围环境的pH值，它们在输送不稳定剂方面特别有用。